• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Isolation of tumour antigen specific scFv's using a chimeric antigen receptor bicistronic retroviral vector in a mammalian screening protocol.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Lipowska-Bhalla, Grazyna
    Gilham, David E
    Hawkins, Robert E
    Rothwell, Dominic G
    Affiliation
    University of Manchester, CIMML, Manchester, United Kingdom
    Issue Date
    2013-09-12
    
    Metadata
    Show full item record
    Abstract
    The clinical potential of chimeric antigen receptors in adoptive cellular therapy is beginning to be realised with several recent clinical trials targeting CD19 showing promising results in advanced B cell malignancies. This increased efficacy corresponds with improved engineering of the chimeric receptors with the latest generation receptors eliciting greater signalling and proliferation potential. However, the antigen binding scFv domain of the receptors is critical in determining the activity of the chimeric receptor expressing T cells; as this determines specificity and affinity to the tumour antigen. In this study, we describe a mammalian T-cell line screening protocol employing a 2A-based bicistronic retroviral vector to isolate functional scFv's. This approach involves expression of the scFv library in a CAR, and is based on selection of clones capable of stimulating CD69 upregulation in a T cell line and has a number of advantages over previously described methods in that the use of a 2A-cassette ensures the exclusion of non-expressing scFv's and the screening using a chimeric receptor in a mammalian T-cell line ensures selection in the optimum context for therapeutic use. Proof of principle experiments show that the protocol was capable of a 105-fold enrichment of positive clones following three rounds of selection. Furthermore, an antigen specific clone was successfully isolated from a partially enriched scFv library confirming the strength of the protocol. This approach has the potential to identify novel scFv's of use in adoptive T cell therapy and, potentially, wider antibody-based applications.
    Citation
    Isolation of tumour antigen specific scFv's using a chimeric antigen receptor bicistronic retroviral vector in a mammalian screening protocol. 2013: Hum Gene Ther Methods
    Journal
    Human Gene Therapy Methods
    URI
    http://hdl.handle.net/10541/302276
    DOI
    10.1089/hgtb.2013.068
    PubMed ID
    24028672
    Type
    Article
    Language
    en
    ISSN
    1946-6544
    ae974a485f413a2113503eed53cd6c53
    10.1089/hgtb.2013.068
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    • Authors: Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L, Moghimi SM
    • Issue date: 2014 Jan
    • One-step expression and purification of single-chain variable antibody fragment using an improved hexahistidine tag phagemid vector.
    • Authors: Zhao Q, Chan YW, Lee SS, Cheung WT
    • Issue date: 2009 Dec
    • Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    • Authors: Ma Q, Gomes EM, Lo AS, Junghans RP
    • Issue date: 2014 Feb
    • Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.
    • Authors: Tassev DV, Cheng M, Cheung NK
    • Issue date: 2012 Feb
    • Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor.
    • Authors: Elinav E, Adam N, Waks T, Eshhar Z
    • Issue date: 2009 May
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.